Study Confirms Long-Lasting Benefit Of Trastuzumab (Herceptin) For Women With Early-S
 

Women with an aggressive type of early-stage breast cancer (HER2-positive disease) given trastuzumab (Herceptin) for one year following standard chemotherapy are at significantly less risk of the cancer returning, and the effect is long lasting, according to the long-term results of the landmark HERA trial published Online First in The Lancet Oncology...

More...